APON(SZ:300753)2026-01-30 07:50Financial Performance - The company expects a net profit loss of approximately -26 million yuan for the year 2025, compared to a profit of 10.8 million yuan in the previous year[4] - The net profit after deducting non-recurring gains and losses is projected to be -30 million yuan, down from 6.23 million yuan in the same period last year[4] - The decline in profit is primarily due to underperformance in the pain management and nasal cavity management business segments, with sales volume decreasing compared to the previous year[6] - Increased competition and price reductions in the market have adversely affected revenue and net profit[6] Non-Recurring Gains and Losses - The company anticipates that non-recurring gains and losses will impact the net profit by approximately 4 million yuan during the reporting period[7] Research and Development - The company is investing more in R&D for new products, including a multi-modal ADHD behavior management system, leading to an increase in R&D expenses compared to the previous year[7] Strategic Plans - The company plans to enhance internal management and focus on the commercialization of new products to achieve sustainable growth in 2026[7] Market Challenges - The nasal care product line faced challenges due to extended clinical development and market entry cycles, as well as intensified price competition[6] Audit and Reporting - The company has communicated with its auditing firm regarding the preliminary financial data, with no significant discrepancies reported[5] - Detailed financial data will be disclosed in the 2025 annual report[8]